Management of Deep Vein Thrombosis in Pregnant Women

Diagnostic Approach

The European Society of Cardiology recommends that all pregnant women with suspected DVT should undergo assessment for pre-test probability, D-dimer testing, and compression ultrasonography 1, 2
Compression ultrasound is the diagnostic imaging procedure of choice for suspected DVT in pregnancy with high sensitivity and specificity for proximal DVT 1
Left-sided DVT is more common (85% of cases) due to compression of the left iliac vein by the right iliac artery and the gravid uterus 1
If a proximal DVT is detected on ultrasound, treatment should be initiated immediately 1
In women with high pre-test probability, a positive D-dimer, and a normal initial compression ultrasound, magnetic resonance venography may be considered to exclude isolated pelvic DVT 1

The American College of Cardiology recommends beginning therapeutic anticoagulation with low-molecular-weight heparin (LMWH) immediately upon diagnosis 3, 4
Either once-daily or twice-daily LMWH dosing regimens can be used, as both have similar efficacy 3, 4
For most pregnant women with low-risk acute DVT, initial outpatient therapy is appropriate rather than hospital admission 3, 4
Routine monitoring of anti-factor Xa levels to guide LMWH dosing is not recommended unless there are specific concerns about therapeutic levels 3, 5

Weight-adjusted LMWH dosing is recommended 1, 4
Options include enoxaparin 1 mg/kg subcutaneously twice daily or enoxaparin 1.5 mg/kg subcutaneously once daily 4

Therapeutic anticoagulation should be maintained throughout pregnancy and for at least 6 weeks postpartum (minimum total duration of 3 months) 4
Vitamin K antagonists (warfarin) should be avoided during pregnancy as they cross the placenta and are associated with embryopathy 4
Catheter-directed thrombolysis is not recommended for routine treatment of DVT in pregnancy 3

Graduated compression stockings should be prescribed, starting within 1 month of DVT diagnosis and continuing for at least 1 year to prevent postthrombotic syndrome 4
Patient education regarding signs and symptoms of pulmonary embolism is essential 1
Schedule follow-up within 1-2 weeks to assess treatment response and complications 1

For pregnant women receiving therapeutic-dose LMWH for DVT management, plan for scheduled delivery with discontinuation of anticoagulant therapy 24 hours before anticipated delivery 3, 4
Anticoagulation can be restarted 8-12 hours after delivery if no significant bleeding is present 4

Do not use vitamin K antagonists (warfarin) during pregnancy due to teratogenic effects 4
Do not rely solely on clinical symptoms for diagnosis as they can be misleading in pregnancy 1
Avoid inadequate duration of anticoagulation; treatment should continue throughout pregnancy and postpartum period 4
Do not use direct oral anticoagulants (DOACs) during pregnancy as safety data is lacking 6, 7

The American Society of Hematology guidelines address the need for immediate evaluation to distinguish between superficial vein thrombosis (SVT) and deep vein thrombosis (DVT) in pregnant patients, as pregnancy-associated venous thromboembolism is a leading cause of maternal morbidity and mortality, and anticoagulation should be initiated if DVT is confirmed, with a recommendation for therapeutic-dose low-molecular-weight heparin (LMWH) in patients with confirmed DVT 8
The American Society of Hematology guidelines also address anticoagulation for proven superficial vein thrombosis in pregnancy, with consideration of conservative management with compression and close monitoring for isolated SVT 8
Consider outpatient management for patients with confirmed DVT who have normal vital signs, no severe pain requiring analgesia, non-extensive thrombosis, no maternal comorbidities, and adequate home support 9